Literature DB >> 26997738

Data-driven desirability function to measure patients' disease progression in a longitudinal study.

Hsiu-Wen Chen1, Weng Kee Wong2, Hongquan Xu3.   

Abstract

Multiple outcomes are increasingly used to assess chronic disease progression. We discuss and show how desirability functions can be used to assess a patient overall response to a treatment using multiple outcome measures and each of them may contribute unequally to the final assessment. Because judgments on disease progression and the relative contribution of each outcome can be subjective, we propose a data-driven approach to minimize the biases by using desirability functions with estimated shapes and weights based on a given gold standard. Our method provides each patient with a meaningful overall progression score that facilitates comparison and clinical interpretation. We also extend the methodology in a novel way to monitor patients' disease progression when there are multiple time points and illustrate our method using a longitudinal data set from a randomized two-arm clinical trial for scleroderma patients.

Entities:  

Keywords:  desirability function; longitudinal data; multiple outcomes; nonlinear least squares; scleroderma

Year:  2015        PMID: 26997738      PMCID: PMC4792097          DOI: 10.1080/02664763.2015.1077378

Source DB:  PubMed          Journal:  J Appl Stat        ISSN: 0266-4763            Impact factor:   1.404


  12 in total

1.  Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score.

Authors:  D M van der Heijde; M A van 't Hof; P L van Riel; L A Theunisse; E W Lubberts; M A van Leeuwen; M H van Rijswijk; L B van de Putte
Journal:  Ann Rheum Dis       Date:  1990-11       Impact factor: 19.103

2.  Identifying promising compounds in drug discovery: genetic algorithms and some new statistical techniques.

Authors:  Abhyuday Mandal; Kjell Johnson; C F Jeff Wu; Dirk Bornemeier
Journal:  J Chem Inf Model       Date:  2007-04-11       Impact factor: 4.956

3.  A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease.

Authors:  Arnold E Postlethwaite; Weng Kee Wong; Philip Clements; Soumya Chatterjee; Barri J Fessler; Andrew H Kang; Joseph Korn; Maureen Mayes; Peter A Merkel; Jerry A Molitor; Larry Moreland; Naomi Rothfield; Robert W Simms; Edwin A Smith; Robert Spiera; Virginia Steen; Kenneth Warrington; Barbara White; Frederick Wigley; Daniel E Furst
Journal:  Arthritis Rheum       Date:  2008-06

4.  The validity of pooled outcome measures (indices) in rheumatoid arthritis clinical trials.

Authors:  M Boers; P Tugwell
Journal:  J Rheumatol       Date:  1993-03       Impact factor: 4.666

5.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Authors:  M L Prevoo; M A van 't Hof; H H Kuper; M A van Leeuwen; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1995-01

6.  Development of composite measures for psoriatic arthritis: a report from the GRAPPA 2010 annual meeting.

Authors:  Philip S Helliwell; Oliver Fitzgerald; Philip J Mease
Journal:  J Rheumatol       Date:  2012-02       Impact factor: 4.666

7.  Relative contributions of the components of the American College of Rheumatology 20% criteria for improvement to responder status in patients with early seropositive rheumatoid arthritis.

Authors:  H E Paulus; K J Bulpitt; B Ramos; G Park; W K Wong
Journal:  Arthritis Rheum       Date:  2000-12

8.  Assessing disease progression using a composite endpoint.

Authors:  Weng Kee Wong; Daniel E Furst; Philip J Clements; Jim B Streisand
Journal:  Stat Methods Med Res       Date:  2007-02       Impact factor: 3.021

9.  Titrating and evaluating multi-drug regimens within subjects.

Authors:  Margaret Shih; Chris Gennings; Vernon M Chinchilli; Walter H Carter
Journal:  Stat Med       Date:  2003-07-30       Impact factor: 2.373

10.  American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.

Authors:  D T Felson; J J Anderson; M Boers; C Bombardier; D Furst; C Goldsmith; L M Katz; R Lightfoot; H Paulus; V Strand
Journal:  Arthritis Rheum       Date:  1995-06
View more
  1 in total

1.  Dual-photon microscopy-based quantitation of fibrosis-related parameters (q-FP) to model disease progression in steatohepatitis.

Authors:  Yan Wang; Robert Vincent; Jinlian Yang; Amon Asgharpour; Xieer Liang; Michael O Idowu; Melissa J Contos; Kalyani Daitya; Mohammed S Siddiqui; Faridoddin Mirshahi; Arun J Sanyal
Journal:  Hepatology       Date:  2017-04-28       Impact factor: 17.425

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.